EP3976038A4 - Composés hétérocycliques en tant qu'inhibiteurs de prmt5 - Google Patents

Composés hétérocycliques en tant qu'inhibiteurs de prmt5 Download PDF

Info

Publication number
EP3976038A4
EP3976038A4 EP20814821.3A EP20814821A EP3976038A4 EP 3976038 A4 EP3976038 A4 EP 3976038A4 EP 20814821 A EP20814821 A EP 20814821A EP 3976038 A4 EP3976038 A4 EP 3976038A4
Authority
EP
European Patent Office
Prior art keywords
heterocyclic compounds
prmt5 inhibitors
prmt5
inhibitors
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20814821.3A
Other languages
German (de)
English (en)
Other versions
EP3976038A1 (fr
Inventor
Wen-Lian Wu
Zhiqiang Yang
Francis Lee
John Qiang TAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angex Pharmaceutical Inc
Original Assignee
Angex Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angex Pharmaceutical Inc filed Critical Angex Pharmaceutical Inc
Publication of EP3976038A1 publication Critical patent/EP3976038A1/fr
Publication of EP3976038A4 publication Critical patent/EP3976038A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP20814821.3A 2019-05-30 2020-05-27 Composés hétérocycliques en tant qu'inhibiteurs de prmt5 Withdrawn EP3976038A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854435P 2019-05-30 2019-05-30
US202062966337P 2020-01-27 2020-01-27
PCT/US2020/034711 WO2020243178A1 (fr) 2019-05-30 2020-05-27 Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Publications (2)

Publication Number Publication Date
EP3976038A1 EP3976038A1 (fr) 2022-04-06
EP3976038A4 true EP3976038A4 (fr) 2023-07-12

Family

ID=73553050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814821.3A Withdrawn EP3976038A4 (fr) 2019-05-30 2020-05-27 Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Country Status (7)

Country Link
EP (1) EP3976038A4 (fr)
JP (1) JP2022534998A (fr)
KR (1) KR20220016194A (fr)
CN (1) CN114126614A (fr)
AU (1) AU2020283505A1 (fr)
CA (1) CA3141855A1 (fr)
WO (1) WO2020243178A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406908A (zh) * 2022-08-09 2024-02-16 大陸商上海湃隆生物科技有限公司 新型prmt5抑制劑及其應用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212385A1 (fr) * 2016-06-06 2017-12-14 Pfizer Inc. Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
WO2019112719A1 (fr) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
WO2018152548A1 (fr) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CA3072439A1 (fr) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Inhibiteurs selectifs de la proteine arginine methyltransferase 5 (prmt5)
AU2018385664B2 (en) * 2017-12-13 2022-06-02 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
JP7446282B2 (ja) * 2018-08-07 2024-03-08 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017212385A1 (fr) * 2016-06-06 2017-12-14 Pfizer Inc. Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
WO2019112719A1 (fr) * 2017-12-05 2019-06-13 Angex Pharmaceutical, Inc. Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUIFENG MAO ET AL: "Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 14, 26 June 2017 (2017-06-26), US, pages 6289 - 6304, XP055682728, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00587 *
See also references of WO2020243178A1 *

Also Published As

Publication number Publication date
WO2020243178A1 (fr) 2020-12-03
CN114126614A (zh) 2022-03-01
JP2022534998A (ja) 2022-08-04
EP3976038A1 (fr) 2022-04-06
AU2020283505A1 (en) 2021-12-23
KR20220016194A (ko) 2022-02-08
CA3141855A1 (fr) 2020-12-03

Similar Documents

Publication Publication Date Title
EP3752491A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
IL274762A (en) Novel heterocyclic compounds as PRMT5 inhibitors
IL290508A (en) Heterocyclic compounds as kinase inhibitors
IL279173A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
IL280762A (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
EP3833355A4 (fr) Inhibiteurs de prmt5
EP3919055A4 (fr) Composé hétérocyclique
EP3997070A4 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de bet
EP3822276A4 (fr) Composé hétérocyclique utilisé en tant qu'inhibiteur de trk
EP3720495A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de prmt5
EP3896060A4 (fr) Composé hétérocyclique
EP3895707A4 (fr) Composé hétérocyclique
EP4077282A4 (fr) Inhibiteurs de prmt5
EP3873474A4 (fr) Composés hétérocycliques utilisés comme inhibiteurs de bet
EP3833669A4 (fr) Inhibiteurs de prmt5
EP3697787A4 (fr) Composé hétérocyclique à utiliser en tant qu'inhibiteur de protéine kinase
EP3833668A4 (fr) Inhibiteurs de prmt5
EP3666770A4 (fr) Nouveaux composés hétérocycliques comme inhibiteurs de cdk8/19
IL289389A (en) Heterocyclic compounds as kinase inhibitors
EP4066893A4 (fr) Composé hétérocyclique
EP3952865A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de kinase pour des utilisations thérapeutiques
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
EP4076459A4 (fr) Inhibiteurs de prmt5
EP4043450A4 (fr) Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac
EP3888652A4 (fr) Composé hétérocyclique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031472500

Ipc: C07H0019140000

A4 Supplementary search report drawn up and despatched

Effective date: 20230609

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20230602BHEP

Ipc: A61P 35/00 20060101ALI20230602BHEP

Ipc: C07D 498/04 20060101ALI20230602BHEP

Ipc: C07D 487/04 20060101ALI20230602BHEP

Ipc: C07D 519/00 20060101ALI20230602BHEP

Ipc: C07H 19/14 20060101AFI20230602BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231201